NCT06244940 The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study
| NCT ID | NCT06244940 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Scripps Translational Science Institute |
| Condition | Congenital Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-09 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2024-01-09 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is enrolling pregnant persons treated at Rady Children's Hospital fetal cardiology program with a prenatal diagnosis of congenital heart disease to look for genetic disorders in the fetus or unborn baby. Congenital heart disease (CHD) is a group of structural differences to the heart that represent the most common birth defect among liveborn infants world-wide. CHD is the leading cause of birth-defect associated infant death. Prenatal detection allows for delivery planning, postnatal repair, specialized medications, and detailed counseling for parents. Up to one in three fetuses with CHD may have a genetic cause. In babies, knowing about genetic diseases helps patients and doctors provide the best care for their babies. If identified prenatally, this same knowledge may help participants prepare for their location of delivery, meet with specialists, and consider specialized treatments and medications that may be appropriate. The diagnostic yield and clinical utility of whole genome sequencing (WGS) in fetuses with prenatally detected congenital heart disease (CHD) will be compared to routine clinical testing in patients choosing amniocentesis or chorionic villus sampling. DNA will be obtained from fetal samples and biological parent blood samples and analyzed according to standard clinical interpretation guidelines. Results will be reported to healthcare providers and patients and measures of clinical utility will be collected. Additionally, measures of stress, anxiety, depression, and perceived utility of information will be assessed by validated survey tools. A historical cohort of patients electing for diagnostic procedures will be used as a comparison population.
Eligibility Criteria
Inclusion Criteria: * Pregnant individual with ongoing pregnancy with prenatally detected fetal CHD * Desire for genetic diagnosis and clinical plan for amniocentesis or chorionic villus sampling Exclusion Criteria: * Gestational age of 38 weeks or greater * Clinical course entirely explained by known chromosomal abnormality or confirmed genetic diagnosis that explains the clinical condition * Pregnant persons under 18 years of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06244940 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Congenital Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06244940 currently recruiting?
Yes, NCT06244940 is actively recruiting participants. Contact the research team at rreimers@scripps.edu for enrollment information.
Where is the NCT06244940 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT06244940 clinical trial?
NCT06244940 is sponsored by Scripps Translational Science Institute. The trial plans to enroll 200 participants.